Cargando…

Oral Semaglutide In The Management Of Type 2 Diabetes: A Report On The Evidence To Date

In recent years, newer drug classes for the treatment of type 2 diabetes mellitus have been released with significant effects on glucose lowering and weight reduction. One of the most promising classes in achieving these goals has been the glucagon-like peptide (GLP)-1 agonists. However, a difficult...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pearson, Sam, Kietsiriroje, Noppadol, Ajjan, Ramzi A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6897065/ https://www.ncbi.nlm.nih.gov/pubmed/31819577 http://dx.doi.org/10.2147/DMSO.S229802

Ejemplares similares

Estimated glucose disposal rate demographics and clinical characteristics of young adults with type 1 diabetes mellitus: A cross-sectional pilot study
por: Nishtala, Revathi, et al.
Publicado: (2020)

The Cellular and Protein Arms of Coagulation in Diabetes: Established and Potential Targets for the Reduction of Thrombotic Risk
por: Safdar, Nawaz Z., et al.
Publicado: (2023)

Risk factors associated with mortality in individuals with type 2 diabetes following an episode of severe hypoglycaemia. Results from a randomised controlled trial
por: Pearson, Sam M, et al.
Publicado: (2022)

The relative contribution of diurnal and nocturnal glucose exposures to HbA1c in type 1 diabetes males: a pooled analysis
por: Campbell, Matthew D., et al.
Publicado: (2022)

Glucose variability is associated with an adverse vascular profile but only in the presence of insulin resistance in individuals with type 1 diabetes: An observational study
por: Kietsiriroje, Noppadol, et al.
Publicado: (2022)

Plasmin Inhibitor in Health and Diabetes: Role of the Protein as a Therapeutic Target
por: Alsayejh, Basmah, et al.
Publicado: (2022)

Management of type 2 diabetes with oral semaglutide: Practical guidance for pharmacists
por: Kane, Michael P, et al.
Publicado: (2020)

A Peptide in a Pill – Oral Semaglutide in the Management of Type 2 Diabetes
por: Selvarajan, Raja, et al.
Publicado: (2023)

Dietary fat intake is associated with insulin resistance and an adverse vascular profile in patients with T1D: a pooled analysis
por: Kietsiriroje, Noppadol, et al.
Publicado: (2022)

Antithrombotic therapy in diabetes: which, when, and for how long?
por: Ajjan, Ramzi A, et al.
Publicado: (2021)

Metabolic Control in Type 1 Diabetes: Is Adjunctive Therapy the Way Forward?
por: Warnes, Harriet, et al.
Publicado: (2018)

The development of an oral GLP-1 receptor agonist for the management of type 2 diabetes: evidence to date
por: Antza, Christina, et al.
Publicado: (2019)

New practice in semaglutide on type-2 diabetes and obesity: clinical evidence and expectation
por: Liu, Yalin, et al.
Publicado: (2022)

Cost-effectiveness of oral semaglutide added to current antihyperglycemic treatment for type 2 diabetes
por: Guzauskas, Gregory F, et al.
Publicado: (2021)

A Pharmacological and Clinical Overview of Oral Semaglutide for the Treatment of Type 2 Diabetes
por: Andersen, Andreas, et al.
Publicado: (2021)

Semaglutide for type 2 diabetes
Publicado: (2020)

Profile of semaglutide in the management of type 2 diabetes: design, development, and place in therapy
por: Gomez-Peralta, Fernando, et al.
Publicado: (2019)

More Unnecessary Imaginary Worlds – Part 2: The ICER Evidence Report on Modeling Oral Semaglutide for Type 2 Diabetes
por: Langley, Paul C
Publicado: (2020)

A Review on Semaglutide: An Oral Glucagon-Like Peptide 1 Receptor Agonist in Management of Type 2 Diabetes Mellitus
por: Kalra, Sanjay, et al.
Publicado: (2020)

Oral Semaglutide
por: Bui, Vinh, et al.
Publicado: (2018)

Profile of Ipragliflozin, an Oral SGLT-2 Inhibitor for the Treatment of Type 2 Diabetes: The Evidence to Date
por: Alkabbani, Wajd, et al.
Publicado: (2021)

Clinical potential of treatment with semaglutide in type 2 diabetes patients
por: Røder, Michael E
Publicado: (2019)

Empagliflozin in the treatment of type 2 diabetes: evidence to date
por: Shubrook, Jay H, et al.
Publicado: (2015)

A Review of Oral Semaglutide Available Evidence: A New Era of Management of Diabetes with Peptide in a Pill Form
por: Kalra, Sanjay, et al.
Publicado: (2022)

Population Pharmacokinetics of Semaglutide for Type 2 Diabetes
por: Overgaard, Rune V., et al.
Publicado: (2019)

Effects of pravastatin, phytosterols, and combination therapy on lipid profile in HIV-infected patients: an open-labelled, randomized cross-over study
por: Kietsiriroje, Noppadol, et al.
Publicado: (2015)

A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes
por: Aroda, Vanita R., et al.
Publicado: (2022)

Efficacy, safety and cardiovascular outcomes of once‐daily oral semaglutide in patients with type 2 diabetes: The PIONEER programme
por: Thethi, Tina K., et al.
Publicado: (2020)

Real-World Use of Once-Weekly Semaglutide in Type 2 Diabetes: Results from SemaglUtide Real-world Evidence (SURE) Germany
por: Menzen, Markus, et al.
Publicado: (2023)

Reduction in cardiovascular mortality following severe hypoglycemia in individuals with type 2 diabetes: the role of a pragmatic and structured intervention: Structured intervention for community hypoglycemia
por: Pearson, Sam M., et al.
Publicado: (2021)

Effect of Oral Semaglutide on Cardiovascular Parameters and Their Mechanisms in Patients with Type 2 Diabetes: Rationale and Design of the Semaglutide Anti-Atherosclerotic Mechanisms of Action Study (SAMAS)
por: Janić, Miodrag, et al.
Publicado: (2022)

A Significant Effect of Oral Semaglutide on Cardiovascular Risk Factors in Patients With Type 2 Diabetes
por: Yanai, Hidekatsu, et al.
Publicado: (2022)

A Review on the Efficacy and Safety of Oral Semaglutide
por: Niman, Stephanie, et al.
Publicado: (2021)

Advances in GLP-1 treatment: focus on oral semaglutide
por: Eliaschewitz, Freddy G., et al.
Publicado: (2021)

SAT-074 Using Ipsilateral and Contralateral Ratios from Adrenal Vein Samples to Identify Functioning Adrenal Adenoma in Patients with Primary Aldosteronism
por: Suntornlohanakul, Onnicha, et al.
Publicado: (2019)

Spotlight on ertugliflozin and its potential in the treatment of type 2 diabetes: evidence to date
por: Cinti, Francesca, et al.
Publicado: (2017)

Oral Semaglutide, the First Ingestible Glucagon-Like Peptide-1 Receptor Agonist: Could It Be a Magic Bullet for Type 2 Diabetes?
por: Kim, Hwi Seung, et al.
Publicado: (2021)

Efficacy and Safety of Subcutaneous and Oral Semaglutide Administration in Patients With Type 2 Diabetes: A Meta-Analysis
por: Zhong, Ping, et al.
Publicado: (2021)

Short-term cost-effectiveness of oral semaglutide for the treatment of type 2 diabetes mellitus in the United States
por: Cui, Jiayu, et al.
Publicado: (2021)

A RESPONSE TO: “COST-EFFECTIVENESS OF ORAL SEMAGLUTIDE ADDED TO CURRENT ANTIHYPERGLYCEMIC TREATMENT FOR TYPE 2 DIABETES”
por: Kohli-Lynch, Ciaran N, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_anbf2g5hcd14cn8dbdmcqc73hl